2021.04.12IR

AnGes’ Phase 1b Trial Demonstrates Safety and Preliminary, Sustained Efficacy 12 Months After a Single Injection of NF-kappa B Oligo DNA Decoy in Subjects with Chronic Discogenic Low Back Pain

2021.03.25IR

COVID-19 Treatment AV-001: Preliminary Positive Phase 1 Clinical Trial Results for Vascular Normalization Therapy

2021.03.18IR

AV-001: Co-development product by Vasomune Therapeutics and AnGes -Vasomune is Pleased to Announce the Government of Canada’s Investment in AV-001 Targeting COVID-19-

2021.03.17IR

Notice of the 22nd Annual General Meeting of Shareholders

2021.03.08IR

AnGes, Inc., a cutting-edge gene therapy and next generation genome editing company, launches USD155.9mm Equity Financing targeting Overseas Institutional Investors to accelerate its effort to become a Global Leader in gene medicines

Learn more